Prognostic value of the quantitative measurement of the oncoprotein p185Her‐2/neu in a group of patients with breast cancer and positive node involvement
Open Access
- 27 August 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 101 (6) , 539-544
- https://doi.org/10.1002/ijc.10612
Abstract
Our study attempts to determine the prognostic value of the quantitative measurement of the oncoprotein p185Her‐2/neu in a group of patients with breast cancer and positive node involvement. In a series of 217 patients with breast cancer and positive nodes in whom the oncoprotein p185 was quantitatively determined by ELISA, we analyzed the clinico‐pathological variables including age, menopausal status, tumor size, number of affected nodes, type and histology grade and the molecular variables such as the oestrogen and progesterone receptors (ER and PR, respectively), pS2 and Cathepsin D (CD). Using 260 fmol/mg protein as a cut‐off point, 18% of the tumors presented as overexpressing p185. The p185 showed no relationship with any of the clinico‐pathological variables studied except that its concentration was elevated in ductal and lobular histology types and in the moderate and poorly differentiated histology grades. With a median follow‐up of 50 months (range 1–90), the univariate analysis of disease‐free survival (DFS) and overall survival (OS) showed that the histology grade, tumor size, the number of infiltrated nodes, the p185 and the ER were the variables associated with the clinical course of the disease in the patients. In the multivariate analysis, however, only the tumor size, number of affected ganglia, the p185 and the ER remained associated with the clinical progression of the disease. The patients with p185 overexpression had a risk, not only of relapse but also death from the disease, of more than twice that of the patients who had normal p185 concentrations. When the p185 was divided into 3 categories based on ±1 × SD above or below the mean, the patients with high and low p185 showed, in the univariate analysis, a similar relationship with DFS but not with OS. In the multivariate analysis, both with the DFS as with the OS, only a high p185 concentration retained its association with the clinical course of the disease in the patients. Our results suggest that by quantitatively determining (using ELISA) the p185 oncoprotein, groups of cancer patients of high risk could be better identified for more effective clinical management.Keywords
This publication has 32 references indexed in Scilit:
- Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocolCancer, 1994
- Correlation of HER-2/neu Amplification With Expression and With Other Prognostic Factors in 1103 Breast CancersJNCI Journal of the National Cancer Institute, 1992
- Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancerInternational Journal of Cancer, 1991
- Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factorsInternational Journal of Cancer, 1991
- c‐erbB‐2 and ras expression levels in breast cancer are correlated and show a co‐operative association with unfavorable clinical outcomeInternational Journal of Cancer, 1991
- c‐erbB‐2 and c‐erbA‐1 (ear‐1) Gene Amplification and c‐erbB‐2 Protein Expression in Japanese Breast Cancers: Their Relationship to the Histology and Other Disease ParametersJapanese Journal of Cancer Research, 1990
- 4. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancerInternational Journal of Cancer, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987